Patrys Limited (PAB.AX)
AUD 0.0
(0.0%)
AUD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -2.24 Million AUD | 26.43% |
| 2023 | -3.04 Million AUD | 61.04% |
| 2022 | -7.81 Million AUD | -13.03% |
| 2021 | -6.91 Million AUD | -73.73% |
| 2020 | -3.98 Million AUD | 38.5% |
| 2019 | -6.47 Million AUD | -40.57% |
| 2018 | -4.6 Million AUD | -141.0% |
| 2017 | -1.91 Million AUD | 40.56% |
| 2016 | -3.21 Million AUD | 30.81% |
| 2015 | -4.64 Million AUD | 46.24% |
| 2014 | -8.64 Million AUD | -65.2% |
| 2013 | -5.23 Million AUD | 15.46% |
| 2012 | -6.18 Million AUD | 0.23% |
| 2011 | -6.2 Million AUD | 8.3% |
| 2010 | -6.76 Million AUD | 29.32% |
| 2009 | -9.57 Million AUD | 37.03% |
| 2008 | -15.19 Million AUD | -1918.57% |
| 2007 | -753 Thousand AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -4.46 Million AUD | 0.0% |
| 2024 FY | -2.24 Million AUD | 26.43% |
| 2024 Q4 | -2.24 Million AUD | 0.0% |
| 2023 Q4 | -3.04 Million AUD | 0.0% |
| 2023 FY | -3.04 Million AUD | 61.04% |
| 2023 Q2 | -3.83 Million AUD | 0.0% |
| 2022 Q4 | -7.81 Million AUD | 0.0% |
| 2022 FY | -7.81 Million AUD | -13.03% |
| 2022 Q2 | -10.76 Million AUD | 0.0% |
| 2021 FY | -6.91 Million AUD | -73.73% |
| 2021 Q2 | -13.16 Million AUD | 0.0% |
| 2021 Q4 | -6.91 Million AUD | 0.0% |
| 2020 Q2 | -5.57 Million AUD | 0.0% |
| 2020 FY | -3.98 Million AUD | 38.5% |
| 2020 Q4 | -3.98 Million AUD | 0.0% |
| 2019 Q4 | -6.47 Million AUD | 0.0% |
| 2019 FY | -6.47 Million AUD | -40.57% |
| 2019 Q2 | -6.07 Million AUD | 0.0% |
| 2018 FY | -4.6 Million AUD | -141.0% |
| 2018 Q2 | -911.77 Thousand AUD | 0.0% |
| 2018 Q4 | -4.6 Million AUD | 0.0% |
| 2017 Q4 | -1.91 Million AUD | 0.0% |
| 2017 FY | -1.91 Million AUD | 40.56% |
| 2017 Q2 | -2.7 Million AUD | 0.0% |
| 2016 FY | -3.21 Million AUD | 30.81% |
| 2016 Q4 | -3.21 Million AUD | 0.0% |
| 2016 Q2 | -4.01 Million AUD | 0.0% |
| 2015 Q2 | -5.44 Million AUD | 0.0% |
| 2015 FY | -4.64 Million AUD | 46.24% |
| 2015 Q4 | -4.64 Million AUD | 0.0% |
| 2014 FY | -8.64 Million AUD | -65.2% |
| 2014 Q4 | -8.64 Million AUD | 0.0% |
| 2014 Q2 | -10.31 Million AUD | 0.0% |
| 2013 Q3 | -5.23 Million AUD | 14.08% |
| 2013 FY | -5.23 Million AUD | 15.46% |
| 2013 Q4 | -5.23 Million AUD | 0.0% |
| 2013 Q1 | -6.08 Million AUD | 1.6% |
| 2013 Q2 | -6.08 Million AUD | 0.0% |
| 2012 Q4 | -6.18 Million AUD | 0.0% |
| 2012 FY | -6.18 Million AUD | 0.23% |
| 2011 Q4 | -6.2 Million AUD | 0.0% |
| 2011 FY | -6.2 Million AUD | 8.3% |
| 2010 Q4 | -6.79 Million AUD | 0.0% |
| 2010 FY | -6.76 Million AUD | 29.32% |
| 2009 Q4 | -9.57 Million AUD | 0.0% |
| 2009 FY | -9.57 Million AUD | 37.03% |
| 2008 Q4 | -15.19 Million AUD | 0.0% |
| 2008 FY | -15.19 Million AUD | -1918.57% |
| 2007 FY | -753 Thousand AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AdAlta Limited | -845.17 Thousand AUD | -165.113% |
| Acrux Limited | -1.45 Million AUD | -53.68% |
| Amplia Therapeutics Limited | -1.82 Million AUD | -22.871% |
| Biome Australia Limited | -1.56 Million AUD | -43.374% |
| BTC Health Limited | -2.02 Million AUD | -10.806% |
| Chimeric Therapeutics Limited | -3.05 Million AUD | 26.608% |
| CSL Limited | 15.76 Billion AUD | 100.014% |
| Clarity Pharmaceuticals Ltd | -136.5 Million AUD | 98.359% |
| Clinuvel Pharmaceuticals Limited | -182.98 Million AUD | 98.776% |
| Noxopharm Limited | -2.31 Million AUD | 3.417% |
| PharmAust Limited | -9.71 Million AUD | 76.934% |
| Proteomics International Laboratories Limited | -6.32 Million AUD | 64.568% |
| Prescient Therapeutics Limited | -10.16 Million AUD | 77.952% |
| PYC Therapeutics Limited | -65.76 Million AUD | 96.593% |
| Race Oncology Limited | -17.18 Million AUD | 86.964% |
| Starpharma Holdings Limited | -19.83 Million AUD | 88.702% |
| EZZ Life Science Holdings Limited | -18.89 Million AUD | 88.144% |
| Botanix Pharmaceuticals Limited | -79.3 Million AUD | 97.175% |
| Memphasys Limited | 4.13 Million AUD | 154.183% |
| Nyrada Inc. | -4.76 Million AUD | 53.02% |
| Anatara Lifesciences Ltd | -982.1 Thousand AUD | -128.148% |
| Telix Pharmaceuticals Limited | -105.79 Million AUD | 97.882% |
| Bio-Gene Technology Limited | -709.55 Thousand AUD | -215.783% |
| Zelira Therapeutics Limited | 5.06 Million AUD | 144.218% |
| Dimerix Limited | -21.99 Million AUD | 89.811% |
| Neuren Pharmaceuticals Limited | -17.09 Million AUD | 86.892% |
| Orthocell Limited | -19.92 Million AUD | 88.754% |
| Imugene Limited | -91.56 Million AUD | 97.553% |
| Cynata Therapeutics Limited | -6.2 Million AUD | 63.892% |
| Immutep Limited | -122.18 Million AUD | 98.166% |
| Arovella Therapeutics Limited | -12.71 Million AUD | 82.377% |
| Alterity Therapeutics Limited | -12.47 Million AUD | 82.046% |
| Nanollose Limited | -96.22 Thousand AUD | -2228.564% |
| Invex Therapeutics Ltd | -6.02 Million AUD | 62.811% |
| NeuroScientific Biopharmaceuticals Limited | -4.95 Million AUD | 54.772% |
| Island Pharmaceuticals Limited | -1.23 Million AUD | -80.931% |
| Biotron Limited | -386.06 Thousand AUD | -480.38% |
| Radiopharm Theranostics Limited | -18.57 Million AUD | 87.937% |
| Tissue Repair Ltd | -16.44 Million AUD | 86.372% |
| AnteoTech Limited | -5 Million AUD | 55.2% |
| Hexima Limited | -2.22 Million AUD | -0.649% |
| Paradigm Biopharmaceuticals Limited | -17.58 Million AUD | 87.256% |
| Recce Pharmaceuticals Ltd | -3.39 Million AUD | 34.023% |
| Avecho Biotechnology Limited | -5.32 Million AUD | 57.955% |
| Actinogen Medical Limited | -9.13 Million AUD | 75.463% |
| Immuron Limited | -11.48 Million AUD | 80.489% |
| Argenica Therapeutics Limited | -15.91 Million AUD | 85.919% |